![](/images/graphics-bg.png)
miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib
المؤلفون المشاركون
Svoboda, Marek
Hezova, Renata
Slaby, Ondrej
Merhautova, Jana
Kovarikova, Alena
Radova, Lenka
Vyzula, Rostislav
Demlova, Regina
Poprach, Alexandr
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-05-03
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Background.
Sunitinib is a tyrosine kinase inhibitor used in the treatment of metastatic renal cell carcinoma.
The main difficulty related to the treatment is the development of drug resistance followed by rapid progression of the disease.
We analyzed tumor tissue of sunitinib treated patients in order to find miRNAs associated with therapeutic response.
Methods.
A total of 79 patients with metastatic renal cell carcinoma were included in our study.
miRNA profiling in tumor tissue samples was performed by TaqMan Low Density Arrays and a group of selected miRNAs (miR-155, miR-374-5p, miR-324-3p, miR-484, miR-302c, and miR-888) was further validated by qRT-PCR.
Normalized data were subjected to ROC and Kaplan-Meier analysis.
Results.
We reported decreased tissue levels of miR-155 and miR-484 as significantly associated with increased time to progression (miR-155: median TTP 5.8 versus 12.8 months, miR-484: median TTP 5.8 versus 8.9 months).
Conclusion.
miR-155 and miR-484 are potentially connected with sunitinib resistance and failure of the therapy.
miR-155 is a known oncogene with direct influence on neovascularization.
Biological role of miR-484 has to be clarified.
Stratification of patients based on miRNA analysis would allow more personalized approach in therapy of metastatic renal cell carcinoma.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Merhautova, Jana& Hezova, Renata& Poprach, Alexandr& Kovarikova, Alena& Radova, Lenka& Svoboda, Marek…[et al.]. 2015. miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. BioMed Research International،Vol. 2015, no. 2015, pp.1-5.
https://search.emarefa.net/detail/BIM-1057324
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Merhautova, Jana…[et al.]. miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. BioMed Research International No. 2015 (2015), pp.1-5.
https://search.emarefa.net/detail/BIM-1057324
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Merhautova, Jana& Hezova, Renata& Poprach, Alexandr& Kovarikova, Alena& Radova, Lenka& Svoboda, Marek…[et al.]. miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-5.
https://search.emarefa.net/detail/BIM-1057324
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1057324
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)